Life Science Investing Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
Life Science Investing Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
Life Science Investing Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.
Life Science Investing Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Goldgroup Enters Into Agreement To Sell Subsidiary Minera Apolo, S.A. de C.V., Disposing of Pinos Project
55 North Mining Appoints Wayne Parsons as Executive Chair; Strengthens Leadership as the Company Advances the Last Hope Gold Project
